On 10 June 2020 Oasmia Pharmaceutical’s CEO Francois Martelet will present at Aktiespararna’s Småbolagsdagar.
The presentation starts at 15:30 CET and will be broadcast live as a webcast at: www.aktiespararna.se/tv/live
The presentation will also be available on Oasmia Pharmaceutical’s website after the seminar.
For more information:
Francois Martelet, CEO of Oasmia
Michael af Winklerfelt, CFO of Oasmia
Phone: +46 18-50 54 40
E-mail: IR@oasmia.com
Consilium Strategic Communications
Jonathan Birt, Chris Welsh
Phone: +44 (0)20 3709 5700
E-mail: oasmia@consilium-comms.com
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops, manufactures, markets and sells an improved generation of drugs within human and veterinary oncology. Oasmia produces novel formulations of well-established cytostatic agents which show improved performance, an improved side-effect profile and a wider range of therapeutic areas compared with existing alternatives. Product development is based on Oasmia’s proprietary technology platform XR-17. Oasmia has been successful in driving its first product candidate, Apealea® (paclitaxel micellar), through clinical development, and has applied for and achieved market approval in the European Union and other territories. Oasmia is in the process of transitioning into the commercialization phase of the product Apealea® and making the product accessible to patients via its partnership with Elevar and its existing operations and partnerships in its retained territories.